4BB.LSE 4BASEBIO UK SOCIETAS

Healthcare Biotechnology London Exchange
5.00 GBX
Close of Nov 3, 2026
420.00 820.00
Market cap
GBX 77.4M
P/E
-
P/B
64.57x
ROE
-2,808.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is 4BB.LSE undervalued?

Graham number

The Graham number of 4BASEBIO UK SOCIETAS cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

4BASEBIO UK SOCIETAS fundamental analysis

No fundamental analysis for 4BASEBIO UK SOCIETAS yet.

4BASEBIO UK SOCIETAS stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About 4BASEBIO UK SOCIETAS

4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and sale of synthetic DNA and RNA products in Europe, the United States, and internationally. It offers hpDNA, a double stranded linear DNA for viral and non-viral vector applications; opDNA, a partially opened, linear, double stranded DNA for in vitro transcription processes that produce mRNA for use in vaccines and therapeutics; oeDNA, a linear, double stranded DNA for genome…

Full company profile